Stockscreener 앱 받기
7.20
4.00%
-0.30
시간 외 거래:
7.20
Arvinas Inc 주식(ARVN)의 최신 뉴스
Arvinas (ARVN) Faces Downgrade Amid Clinical Trial Results | ARV - GuruFocus
Arvinas (ARVN) Announces Promising Phase 3 Trial Results for Vepdegestrant | ARVN Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression - WTVB
Arvinas (NASDAQ:ARVN) Shares Down 4.7%What's Next? - MarketBeat
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
Pfizer and Arvinas Plan FDA Submission for Breast Cancer Drug - GuruFocus
Pfizer, Arvinas report positive breast cancer drug trial - breakingthenews.net
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2 - Seeking Alpha
(ARVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Voloridge Investment Management LLC Makes New Investment in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas And Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival For Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer - marketscreener.com
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progre - GuruFocus
Is Trump Media Stock a Buy After $2.5 Billion Bitcoin Treasury Deal? - The Globe and Mail
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect? - MSN
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer - BioPharma Dive
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - GlobeNewswire
#ASCO25: Arvinas, Pfizer’s PROTAC in breast cancer no better than oral SERDs - Endpoints News
Here Are My Top 3 High-Yield Pipeline Stocks to Buy Now - The Globe and Mail
3 Dividend Stocks to Buy With $500 and Hold Forever - The Globe and Mail
Arvinas (NASDAQ:ARVN) Trading Up 7.9%Still a Buy? - MarketBeat
Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Arvinas to Present at Jefferies Global Healthcare Conference | ARVN Stock News - GuruFocus
Protein Degradation Pioneer Arvinas Reveals Latest Progress at Major Jefferies Healthcare Conference - Stock Titan
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Two Sigma Advisers LP - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm - Yahoo Finance
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN) - Business Wire
Prediction: 2 AI Stocks Will Be Worth More Than Apple Stock Before the End of 2026 - The Globe and Mail
3 Top High-Yield Dividend Stocks to Buy and Hold Through at Least the End of the Decade - The Globe and Mail
Costco (COST) Is About to Report Q3 Earnings. Here’s What to Expect - The Globe and Mail
USDJPY Faces An Intraday Corrective Recovery: Elliott Wave Intraday Analysis - The Globe and Mail
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks By Investing.com - Investing.com South Africa
Woodline Partners LP Boosts Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks - Investing.com
Twinbeech Capital LP Acquires New Stake in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Northern Trust Corp Buys 42,638 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire
BNP Paribas Financial Markets Purchases 7,243 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the Firm - TradingView
RTW Investments LP Raises Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
(ARVN) Proactive Strategies - news.stocktradersdaily.com
Patient Square Capital LP Acquires New Shares in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Northern Trust Corp Purchases 42,638 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
UBS Group Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - Defense World
Arvinas (ARVN) Price Target Slashed by UBS but Rating Maintained | ARVN Stock News - GuruFocus
UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating - marketscreener.com
Arvinas (ARVN) Faces Price Target Reduction Amid Trial Changes | - GuruFocus
Arvinas (ARVN) Faces Price Target Reduction Amid Trial Changes | ARVN Stock News - GuruFocus
Dimensional Fund Advisors LP Acquires 186,254 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Cantor Fitzgerald Lifts Earnings Estimates for Arvinas - MarketBeat
ATTENTION ARVN SHAREHOLDERS: Investors Who Lost Money on Arvinas, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
1.89%
3.74%
자본화:
|
볼륨(24시간):